|Table of Contents|

Research progress of non-coding RNA regulating pyroptosis in the pathogenesis of lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 18
Page:
3581-3588
Research Field:
Publishing date:

Info

Title:
Research progress of non-coding RNA regulating pyroptosis in the pathogenesis of lung cancer
Author(s):
XIE Yingying1; 2; ZHANG Xiaoqing3; MA Chunzheng1; LI Dongdong1; HU Yiyang1; 2; ZHAO Ningning1; 2; ZHANG Juan1; 2
1.The Second Affiliated Hospital of Henan University of Chinese Medicine,Henan Zhengzhou 450002,China;2.The Second Clinical Medical College,Henan University of Chinese Medicine,Henan Zhengzhou 450046，China;3.The First Affiliated Hospital of Zhengzhou University，Henan Zhengzhou 450052，China.
Keywords:
non-coding RNA; pyroptosis; lung cancer
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.18.029
Abstract:
Lung cancer is the most common type of cancer in China,and its high morbidity and mortality make it a major public health problem in China.Pyroptosis is a new form of programmed cell death.More and more studies have confirmed that non-coding RNAs,such as miRNA,lncRNA and circRNA,play an important role in the occurrence and development,drug resistance and prognosis of lung cancer by regulating pyroptosis.At present,the research on the regulation of pyroptosis by non-coding RNA mainly focuses on improving the sensitivity of radiotherapy and chemotherapy,prognosis and synergy of lung cancer.This article briefly introduces pyroptosis,and reviews the latest research progress of non-coding RNA regulating pyroptosis in lung cancer cells,in order to reveal the mechanism of non-coding RNA regulating pyroptosis in lung cancer cells,so as to provide new ideas for elucidating the involvement of pyroptosis in the occurrence and development of lung cancer from the perspective of non-coding RNA,and then provide new targets and new strategies for the treatment of lung cancer.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ ZHAO J，SHI YL，WANG YT，et al.Lung cancer risk attributable to active smoking in China:A systematic review and meta-analysis［J］.Biomed Environ Sci，2023，36(9):850-861.
［3］ THAI AA，SOLOMON BJ，SEQUIST LV，et al.Lung cancer［J］.Lancet，2021，398(10299):535-554.
［4］ LIU P，ZHAO Q，XU Y，et al.A Chinese classical prescription Qianjinweijing Decoction in treatment of lung cancer:An overview［J］.Biomedicine & Pharmacotherapy，2022，156:113913.
［5］ LI J，ZHU L，KWOK HF，et al.Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment［J］.Drug Resistance Updates，2023，66:100904.
［6］ TANG R，XU J，ZHANG B，et al.Ferroptosis，necroptosis，and pyroptosis in anticancer immunity［J］.Journal of Hematology & Oncology，2020，13(1):110.
［7］ GAO W，WANG X，ZHOU Y，et al.Autophagy，ferroptosis，pyroptosis，and necroptosis in tumor immunotherapy［J］.Signal Transduction and Targeted Therapy，2022，7(1):196.
［8］ FANG Y，TIAN S，PAN Y，et al.Pyroptosis:A new frontier in cancer［J］.Biomedicine & Pharmacotherapy，2020，121:109595.
［9］ RAO Z，ZHU Y，YANG P，et al.Pyroptosis in inflammatory diseases and cancer［J］.Theranostics，2022，12(9):4310-4329.
［10］ DU T，GAO J，LI P，et al.Pyroptosis，metabolism，and tumor immune microenvironment［J］.Clinical and Translational Medicine，2021，11(8):e492.
［11］ LI L，JIANG M，QI L，et al.Pyroptosis，a new bridge to tumor immunity［J］.Cancer Science，2021，112(10):3979-3994.
［12］ HSU SK，LI CY，LIN IL，et al.Inflammation-related pyroptosis,a novel programmed cell death pathway,and its crosstalk with immune therapy in cancer treatment［J］.Theranostics，2021，11(18):8813-8835.
［13］ YU P，ZHANG X，LIU N，et al.Pyroptosis:mechanisms and diseases［J］.Signal Transduction and Targeted Therapy，2021，6(1):128.
［14］ VALLONE C，RIGON G，GULIA C，et al.Non-coding RNAs and endometrial cancer［J］.Genes (Basel)，2018，9(4):187.
［15］ ZHAN L，LI J，WEI B，et al.Long non-coding RNAs in ovarian cancer［J］.J Exp Clin Cancer Res，2018，37(1):120.
［16］ 牛亚倩，常钰玲，刘芳,等.microRNA在肝细胞癌有氧糖酵解中的调控作用［J］.临床肝胆病杂志，2019，35(09):2082-2084. NIU YQ，CHANG YL，LIU F，et al.Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma［J］.J Clin Hepatol，2019，35(09):2082-2084.
［17］ 段艺菲，赵清喜，荆雪.长链非编码RNA对原发性肝癌中糖酵解途径的影响机制［J］.临床肝胆病杂志，2019，35(06):1374-1376. DUAN YF，ZHAO QX，JING X.Effect of long non-coding RNAs on glycolytic pathway in primary liver cancer and related mechanisms［J］.J Clin Hepatol，2019，35(06):1374-1376.
［18］ 张军，欧阳满照.非编码RNA在结肠癌糖代谢重编程中的作用［J］.海南医学，2022，33(10):1317-1323. ZHANG J，OUYANG MZ.Role of non-coding RNA in glucose reprogramming in colon cancer［J］.Hainan Med J，2022，33(10):1317-1323.
［19］ SHI F，ZHANG L，LIU X，et al.Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death［J］.Bioengineered，2021，12(1):6332-6342.
［20］ JIANG R，LU B，FENG F，et al.The sodium new houttuyfonate suppresses NSCLC via activating pyroptosis through TCONS-14036/miR-1228-5p/PRKCDBP pathway［J］.Cell Proliferation，2023，56(7):e13402.
［21］ SONG J，SUN Y，CAO H，et al.A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma［J］.Bioengineered，2021，12(1):5932-5949.
［22］ DAI J，QU T，YIN D，et al.LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer［J］.Cell Death & Disease，2023，14(5):312.
［23］ LIU J，YAO L，ZHANG M，et al.Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death［J］.Aging，2019，11(18):7830-7846.
［24］ HUANG H，SHI Z，LI Y，et al.Pyroptosis-related lncRNA signatures correlate with lung adenocarcinoma prognosis［J］.Frontiers in Oncology，2022，12:850943.
［25］ ZHANG Y，WANG Y，YIN X，et al.Identification of pyroptosis-related long non-coding RNAs with prognosis and therapy in lung squamous cell carcinoma［J］.Scientific Reports，2022，12(1):11206.
［26］ XU X，ZHOU X，CHEN Z，et al.Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin［J］.Aging，2020，12(6):4711-4726.
［27］ ZHOU S，CAI Y，XU Z，et al.Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis,metabolism signals and immune infiltration in lung adenocarcinoma［J］.Frontiers in Endocrinology，2022，13:964362.
［28］ 潘金清，汤佳馨，周佳敏,等.基于焦亡相关lncRNAs的肺鳞癌预后风险模型［J］.南昌大学学报(医学版)，2022，62(06):25-31. PAN JQ，TANG JX，ZHOU JM，et al.Prognostic risk model of lung squamous cell carcinoma based on pyroptosis related-lncRNAs［J］.Journal of Nanchang University(Medical Sciences)，2022，62(06):25-31.
［29］ LIU J，LIU Q，SHEN H，et al.Identification and validation of a three pyroptosis-related lncRNA signature for prognosis prediction in lung adenocarcinoma［J］.Frontiers in Genetics，2022，13:838624.
［30］ ZHOU W，ZHANG W.A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma［J］.BMC Cancer，2022，22(1):694.
［31］ MA C，LI F，GU Z，et al.A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis，immune infiltration，and immunotherapy response in lung adenocarcinoma［J］.Frontiers in Pharmacology，2023，14:1146840.
［32］ LUO P，JIANG Y，DING S，et al.Integrative analysis of pyroptosis-related prognostic signature and immunological infiltration in lung squamous cell carcinoma［J］.BioMed Research International，2022，2022:4944758.
［33］ ZHANG T，WU DM，LUO PW，et al.CircNEIL3 mediates pyroptosis to influence lung adenocarcinoma radiotherapy by upregulating PIF1 through miR-1184 inhibition［J］.Cell Death & Disease，2022，13(2):167.
［34］ XIE X，DING F，XIAO H.Knockdown of hsa_circ_0000729 inhibits the tumorigenesis of non-small cell lung cancer through mediation of miR-1281/FOXO3 axis［J］.Cancer Management and Research，2021，13:8445-8455.
［35］ DAI C，MA Z，SI J，et al.Hsa_circ_0007312 promotes third-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance through pyroptosis and apoptosis via the miR-764/MAPK1 axis in lung adenocarcinoma cells［J］.Journal of Cancer，2022，13(9):2798-2809.
［36］ ZHANG Z，CHEN Q，HUANG C，et al.Transcription factor Nrf2 binds to circRNAPIBF1 to regulate SOD2 in lung adenocarcinoma progression［J］.Molecular Carcinogenesis，2022，61(12):1161-1176.
［37］ 李磊,钟敏钰,郭培中，等.化疗联合CIK细胞免疫治疗治疗小细胞肺癌［J］.现代肿瘤医学，2016,24(15):2406-2409. LI L,ZHONG MY,GUO PZ,et al.Clinical research of small cell lung cancer patients treated with chemotherapy combined with CIK［J］.Modern Oncology,2016,24(15):2406-2409.
［38］ 赵丽霞,赵峻峰,张敬，等.胸部放疗在广泛期小细胞肺癌治疗中的作用［J］.现代肿瘤医学，2016,24(24):3934-3937. ZHAO LX,ZHAO JF,ZHANG J,et al.Role of thoracic radiotherapy in the treatment for patients with extensive stages of small cell lung cancer［J］.Modern Oncology,2016,24(24):3934-3937.
［39］ JIA Y，WANG X，DENG Y，et al.Pyroptosis provides new strategies for the treatment of cancer［J］.Journal of Cancer，2023，14(1):140-151.

Memo

Memo:
National Natural Science Foundation of China(No.82204981);国家自然科学基金资助项目(编号：82204981)；河南省特色骨干学科中医学学科建设项目（编号：STG-ZYX06-202145）；河南省中医药科学研究专项项目(编号：2021JDZX2002，20-21ZY2115）；河南省中医院博士科研基金项目（编号：2022BSJJ08，2023BSJJ02）；河南中医药大学研究生科研创新项目（编号：2022KYCX057）
Last Update: 1900-01-01